The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...

The sBLA is supported by results from the pivotal phase 3 TROPION-Breast02 clinical trial (NCT05374512), which evaluated the efficacy and safety of Dato-DXd compared with the investigator’s choice of ...

Priority Review was granted by FDA for the first line metastatic TNBC treatment. Datroway significantly improved survival ...

By targeting proteins used to splice genes, UC San Diego researchers have unlocked a new approach to treating triple-negative ...

DATROWAY Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy ...

A new experimental vaccine could slow down triple negative breast cancer and reduce its recurrence after treatment.

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for DATROWAY® (datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the US for the treatment ...

Antal and Yeo, who also are members of UCSD’s Moores Cancer Center, say the key to targeting triple-negative breast cancer, or TNBC, is managing a protein called poly (U)-binding splicing factor 60, ...

Medically reviewed by Marla Anderson, MD Key Takeaways Triple-negative breast cancer is aggressive and often resists ...

Significantly longer progression-free survival seen among patients with previously untreated, PD-L1 advanced or metastatic ...

The Cleveland Clinic is out with its findings on a vaccine to prevent breast cancer.